| Title |
Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
|
|---|---|
| Published in |
CNS Drugs, December 2018
|
| DOI | 10.1007/s40263-018-0586-5 |
| Pubmed ID | |
| Authors |
Jeremy Hobart, Tjalf Ziemssen, Peter Feys, Michael Linnebank, Andrew D. Goodman, Rachel Farrell, Raymond Hupperts, Andrew R. Blight, Veronica Englishby, Manjit McNeill, Ih Chang, Gabriel Lima, Jacob Elkins |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 2 | 18% |
| United States | 1 | 9% |
| Unknown | 8 | 73% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 91% |
| Practitioners (doctors, other healthcare professionals) | 1 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 187 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 187 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 17 | 9% |
| Student > Bachelor | 16 | 9% |
| Student > Ph. D. Student | 13 | 7% |
| Researcher | 13 | 7% |
| Student > Master | 13 | 7% |
| Other | 35 | 19% |
| Unknown | 80 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 18% |
| Nursing and Health Professions | 21 | 11% |
| Neuroscience | 13 | 7% |
| Unspecified | 9 | 5% |
| Sports and Recreations | 7 | 4% |
| Other | 17 | 9% |
| Unknown | 87 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 January 2019.
All research outputs
#3,160,916
of 23,117,738 outputs
Outputs from CNS Drugs
#288
of 1,319 outputs
Outputs of similar age
#73,463
of 436,845 outputs
Outputs of similar age from CNS Drugs
#5
of 16 outputs
Altmetric has tracked 23,117,738 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,319 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.3. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 436,845 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.